Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BDA-366 |
| Synonyms | |
| Therapy Description |
BDA-366 is a small molecule selective inhibitor of BCL2 that targets the BH4 domain and induces pro-apoptotic activity, potentially resulting in increased tumor cell apoptosis (PMID: 26004684, PMID: 30047840). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BDA-366 | BCL2 inhibitor 29 | BDA-366 is a small molecule selective inhibitor of BCL2 that targets the BH4 domain and induces pro-apoptotic activity, potentially resulting in increased tumor cell apoptosis (PMID: 26004684, PMID: 30047840). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|